United States Drug Patent 8,119,648: Linagliptin Claims, Scope, Expiration, and Patent Landscape

U.S. Patent No. 8,119,648 protects methods of treating type 2 diabetes mellitus and obesity with linagliptin, including specified salts and pharmaceutical compositions. The patent does not claim linagliptin as a chemical compound or claim a manufacturing process. Its commercial value therefore depends on the asserted treatment indication, the product label, Orange Book listings, and the timing of generic entry.

The patent was assigned to Boehringer Ingelheim International GmbH and covers the active ingredient marketed as Tradjenta in the United States. The stated patent expiration date is August 18, 2026, subject to the operative term shown in the USPTO and FDA records. [1][2]

What drug does U.S. Patent 8,119,648 protect?

The patent protects linagliptin, a xanthine-based dipeptidyl peptidase-4, or DPP-4, inhibitor.

The claimed compound is:

1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine

The compound is commonly identified as linagliptin. Tradjenta is the principal U.S. product associated with the patent. Linagliptin is also marketed in combination products, including:

Tradjenta, linagliptin tablets
Jentadueto, linagliptin and metformin hydrochloride
Jentadueto XR, extended-release linagliptin and metformin hydrochloride
Glyxambi, linagliptin and empagliflozin

The claims in Patent 8,119,648 focus on treatment methods rather than the product’s chemical composition. That distinction affects generic litigation and post-expiration launch risk.

What are the independent claims in U.S. Patent 8,119,648?

The material independent claims are claims 1, 2, 4, 5, 7, 8, 9, and 10.

Claim	Primary subject matter	Indication
1	Method using a defined compound formula with specified R groups, including linagliptin and salts	Type 2 diabetes or obesity
2	Method using linagliptin specifically	Type 2 diabetes or obesity
4	Method using a pharmaceutical composition containing the claimed compound	Type 2 diabetes or obesity
5	Method using linagliptin or a physiologically acceptable acid salt	Type 2 diabetes or obesity
7	Method using linagliptin	Type 2 diabetes
8	Method using linagliptin	Obesity
9	Pharmaceutical composition method using linagliptin	Type 2 diabetes
10	Pharmaceutical composition method using linagliptin	Obesity

Claims 3 and 6 are dependent claims. Claim 3 addresses pharmaceutically acceptable salts. Claim 6 narrows claim 5 to treatment of type 2 diabetes.

The reference in claim 7 to “methyl1” appears to be a transcription or typographical error for the methyl-substituted quinazolinylmethyl group. Claim construction would rely on the issued patent, prosecution history, specification, and certificate data rather than an informal reproduction of the claim text.

How broad is the scope of Patent 8,119,648?

The patent has a narrow chemical scope but potentially broad use coverage.

Chemical scope

Claim 1 specifies:

A 4-methyl-2-quinazolinylmethyl group at R1
A methyl group at R2
A 2-butyn-1-yl group at R3
The claimed xanthine structure
Linagliptin’s stereochemical configuration
Enantiomers, mixtures, and salts

Claims 2 and 5 through 10 narrow the subject matter to linagliptin itself or its physiologically acceptable salts.

The claim set does not cover every DPP-4 inhibitor. It does not reach sitagliptin, saxagliptin, alogliptin, vildagliptin, or other structurally unrelated products.

Therapeutic scope

The therapeutic scope includes:

Treatment of type 2 diabetes mellitus
Treatment of obesity
Administration to a patient in need
A pharmaceutically effective amount
Administration of the active ingredient alone or in a pharmaceutical composition

The patent does not expressly limit treatment to a particular dose, dosing frequency, tablet strength, patient age, renal function, or combination therapy. The absence of detailed dosing limitations increases the potential relevance of the claims to ordinary linagliptin products.

Formulation scope

Claims 4, 9, and 10 cover administration of a pharmaceutical composition containing linagliptin, optionally with inert carriers or diluents.

These claims do not appear to require a particular:

Tablet technology
Coating system
Excipient
Release profile
Particle size
Crystalline form
Manufacturing process
Fixed-dose combination

The formulation claims provide a second infringement theory for a generic product that is sold with the patented treatment indication. They do not operate as broad composition-of-matter claims.

Is U.S. Patent 8,119,648 a composition-of-matter patent?

No. U.S. Patent 8,119,648 is principally a method-of-use patent.

That distinction has three consequences:

The patent does not prevent all manufacture or sale of linagliptin after expiration of other relevant patents.
Infringement generally depends on the accused product being indicated, promoted, prescribed, or used for a patented method.
A generic applicant may attempt a Paragraph IV certification, a section viii statement, or a label carve-out depending on the Orange Book listing and the remaining approved uses.

A separate linagliptin compound patent, U.S. Patent No. 7,407,955, formed part of the earlier composition-of-matter estate. Its expiration did not eliminate later method, formulation, crystalline-form, or combination-product patents. [3]

What is the expiration date of U.S. Patent 8,119,648?

The listed expiration date is August 18, 2026.

Event	Date or status
Priority basis	2006 priority filing, as reflected in patent records
U.S. patent issue	February 21, 2012
Patent number	U.S. 8,119,648
Patent type	Method of treatment and pharmaceutical composition use
Stated expiration	August 18, 2026
Patent term extension	No generally applicable extension should be assumed for this patent
Commercial relevance	Protects labeled and potentially induced uses of linagliptin before expiration

The patent’s term is separate from FDA regulatory exclusivity. FDA new chemical entity exclusivity for Tradjenta expired years before the patent term. FDA approval was granted in 2011, while the patent remains the more important barrier for the listed uses. [2][4]

What is the Orange Book status of U.S. Patent 8,119,648?

Patent 8,119,648 has been associated with the Orange Book patent listings for linagliptin products, including Tradjenta. The relevant listing is a method-of-use listing rather than a product-by-process or manufacturing listing.

The listing matters because an ANDA applicant referencing linagliptin must address the listed patent through one of the statutory certification pathways:

Paragraph I: no patent information has been filed
Paragraph II: the patent has expired
Paragraph III: the applicant will wait until expiration
Paragraph IV: the patent is invalid, unenforceable, or will not be infringed

For this patent, a Paragraph IV certification before August 18, 2026 could trigger Hatch-Waxman litigation under 35 U.S.C. § 271(e)(2). A timely suit by the patent owner or NDA holder could invoke the statutory 30-month stay, subject to court action and applicable procedural rules. [5]

The practical impact depends on whether the generic label includes diabetes treatment, obesity treatment, or both. A label limited to non-patented indications may reduce method-of-use exposure, but a generic linagliptin product intended to substitute for Tradjenta faces greater risk if its labeling, product literature, or marketing supports the patented use.

How do the claims affect Paragraph IV challenges?

A Paragraph IV challenge would likely focus on claim construction, validity, and induced infringement.

Potential invalidity issues

Potential defenses could include:

Lack of novelty based on earlier linagliptin treatment disclosures
Obviousness based on prior DPP-4 inhibitor research
Written-description or enablement challenges
Indefiniteness involving the formula or stereochemical terminology
Double-patenting issues involving related linagliptin patents
Prosecution-history estoppel affecting claim scope

The patent’s narrower species claims may be more resilient against generic prior-art attacks than a broad genus claim. Claims 7 through 10 are particularly specific because they identify linagliptin and the diabetes or obesity indication.

Potential infringement theories

The patent owner could assert:

Direct infringement by administration of linagliptin for a covered indication
Induced infringement based on product labeling, prescribing information, promotional materials, or distribution practices
Contributory infringement in circumstances involving substantial noninfringing use and other statutory requirements

An ANDA applicant may seek to avoid infringement by removing a patented indication from its label. That strategy is more difficult where the product’s remaining label, dosage instructions, or marketing materials still encourage the patented use.

What formulations are protected by Patent 8,119,648?

The patent’s composition claims cover pharmaceutical compositions containing linagliptin, with optional inert carriers or diluents.

The claims are broad at the functional level, but they do not appear to claim every possible formulation detail. They can reach conventional oral solid dosage forms where:

Linagliptin is present in a pharmaceutically acceptable amount
The product is administered for type 2 diabetes or obesity
The composition includes ordinary excipients or diluents

The patent does not, based on the quoted claims, specifically require:

A particular crystalline polymorph
A specific salt form
A defined dissolution profile
A controlled-release matrix
A particular tablet coating
A fixed-dose combination with metformin or empagliflozin

Separate formulation or solid-state patents may therefore remain relevant even after Patent 8,119,648 expires. An ANDA clearance analysis must review the complete Orange Book listing for each linagliptin product, not only this patent.

Does the patent cover Jentadueto, Jentadueto XR, and Glyxambi?

The patent can be relevant to combination products containing linagliptin when those products are used to treat type 2 diabetes.

The quoted claims do not expressly require metformin or empagliflozin. Accordingly, the patent’s application to combination products depends on whether the combination product administers linagliptin for the claimed indication and whether the relevant product and use fall within the claim language.

Product	Active ingredients	Relevance of Patent 8,119,648
Tradjenta	Linagliptin	Directly relevant
Jentadueto	Linagliptin and metformin	Potentially relevant to linagliptin component and use
Jentadueto XR	Extended-release linagliptin and metformin	Potentially relevant, subject to product-specific listings
Glyxambi	Linagliptin and empagliflozin	Potentially relevant to the linagliptin treatment method

Combination-product patents, extended-release formulation patents, and crystalline-form patents must be evaluated separately. Patent 8,119,648 alone does not establish the complete exclusivity position for any combination product.

Which companies have challenged linagliptin patents?

Generic manufacturers that have pursued or prepared ANDA strategies for linagliptin products have included major U.S. and international generic companies. Public patent disputes involving Tradjenta and related linagliptin products have centered on Orange Book-listed patents, including method, compound, formulation, and solid-state rights.

The most commercially relevant challengers are expected to include companies with established diabetes portfolios and ANDA capabilities, such as:

Teva
Mylan or Viatris
Sandoz
Lupin
Sun Pharmaceutical
Zydus
Dr. Reddy’s Laboratories
Alembic
Aurobindo

The existence of an ANDA filing or Paragraph IV certification does not establish a launch date. A launch may depend on litigation settlements, 30-month stays, tentative FDA approval, other listed patents, and any contractual restrictions.

What patent litigation affects U.S. Patent 8,119,648?

The principal litigation risk arises under the Hatch-Waxman framework.

A generic applicant that files a Paragraph IV certification can be sued in federal district court. The litigation would typically address:

Whether the claims cover the proposed generic label
Whether the patent is valid and enforceable
Whether the generic label induces infringement
Whether a carved-out indication is legally sufficient
Whether related patents independently block approval or launch

Settlement agreements may provide an authorized generic arrangement, a delayed generic entry date, a license, or a covenant not to sue. A settlement involving one patent does not necessarily resolve all linagliptin patents or all products.

A definitive launch date should therefore be based on the latest court docket, settlement terms, FDA approval status, and Orange Book records rather than on the expiration date of Patent 8,119,648 alone.

What is the competitive landscape for linagliptin?

Linagliptin competes within the DPP-4 inhibitor class and against newer glucose-lowering classes.

Product	Sponsor or major originator	Class	Patent-risk profile
Tradjenta	Boehringer Ingelheim and Eli Lilly	DPP-4 inhibitor	Patent and generic-entry exposure
Januvia	Merck	DPP-4 inhibitor	Separate sitagliptin estate
Onglyza	AstraZeneca	DPP-4 inhibitor	Separate saxagliptin estate
Nesina	Takeda	DPP-4 inhibitor	Separate alogliptin estate
Jardiance	Boehringer Ingelheim and Eli Lilly	SGLT2 inhibitor	Competes clinically and commercially
Ozempic and Rybelsus	Novo Nordisk	GLP-1 receptor agonist	Stronger injectable and oral incretin competition
Mounjaro	Eli Lilly	GIP/GLP-1 agonist	High-growth metabolic competitor

Linagliptin has clinical differentiation in renal impairment because it generally does not require the same degree of renal dose adjustment associated with certain competing DPP-4 inhibitors. That commercial feature does not expand the legal scope of Patent 8,119,648.

How strong is the patent estate for linagliptin?

Patent 8,119,648 is a meaningful but time-limited component of the linagliptin estate.

Strengths

Claims the marketed active ingredient by name
Covers both diabetes and obesity treatment
Includes active ingredient and pharmaceutical composition methods
Includes salts and stereochemically defined linagliptin
Does not require a narrow dose or formulation
Can support induced-infringement allegations based on labeling

Limitations

It is not a composition-of-matter claim
It does not claim every linagliptin manufacturing process
It does not expressly claim every fixed-dose combination
Obesity use may be less commercially important than diabetes use
Generic applicants may attempt indication carve-outs
The patent expires in 2026
Other patents may determine the actual launch date

The patent is strongest against a generic label that reproduces the full Tradjenta diabetes indication and dosing information. Its relative value is lower where the applicant removes patented indications and avoids promotional conduct encouraging the claimed methods.

What generic launch scenarios exist?

Scenario 1: Launch after patent expiration

A generic applicant waits until August 18, 2026, or until all blocking patents expire or are otherwise resolved. This is the lowest litigation-risk path.

Scenario 2: Paragraph IV launch after litigation

The applicant certifies that Patent 8,119,648 is invalid, unenforceable, or not infringed, defeats or settles litigation, and launches before the listed expiration date.

Scenario 3: Carved-label launch

The applicant removes a patented indication under a section viii statement. This may permit launch for remaining non-patented indications, but the strategy depends on FDA labeling rules and whether the remaining label still encourages the patented use.

Scenario 4: Authorized generic or license

The originator or an affiliated company supplies an authorized generic or licenses a generic manufacturer. This can alter the economic impact of the first independent generic launch.

The most important commercial risk is not simply the patent’s nominal expiration date. It is the interaction between the patent, Orange Book listings for related products, litigation settlements, and the final approved generic label.

What manufacturing and geographic rights does the patent cover?

The claims are directed to U.S. treatment and composition use. They do not expressly claim a manufacturing process, synthetic intermediate, polymorph, or production facility.

A company manufacturing linagliptin outside the United States may still face U.S. exposure if it:

Imports the product into the United States
Supplies an ANDA applicant for U.S. sale
Uses the product in a way covered by the U.S. method claims
Produces the product for a U.S.-directed commercial program

U.S. Patent 8,119,648 does not establish global exclusivity. Parallel patents in Europe, Japan, China, Canada, and other jurisdictions must be analyzed separately. Patent expiration dates may differ because of national filing dates, supplementary protection certificates, patent-term adjustments, and local prosecution history.

Key Takeaways

U.S. Patent 8,119,648 is a linagliptin method-of-use patent associated with Tradjenta.
The central claims cover treatment of type 2 diabetes and obesity with linagliptin or its pharmaceutically acceptable salts.
Claims 4, 9, and 10 extend the method coverage to pharmaceutical compositions with carriers or diluents.
The patent does not claim linagliptin as a composition of matter or claim a manufacturing process.
The stated expiration date is August 18, 2026.
A generic linagliptin applicant may face Paragraph IV litigation, induced-infringement allegations, or the need for an indication carve-out.
Patent 8,119,648 should be reviewed together with the separate compound, formulation, crystalline-form, and combination-product patents listed for Tradjenta and related products.
There is no biosimilar pathway for linagliptin. The relevant competitors are ANDA-based small-molecule generics.
The actual generic launch date depends on litigation, settlements, FDA approval, label design, and other Orange Book patents.

FAQs About U.S. Patent 8,119,648 and Linagliptin

Is U.S. Patent 8,119,648 a patent on Tradjenta itself?

No. It is principally a method-of-treatment patent covering the use of linagliptin for type 2 diabetes and obesity. Other patents may protect the compound, formulations, crystalline forms, or combination products.

Can a generic company sell linagliptin before August 18, 2026?

It may be possible through a successful Paragraph IV challenge, a settlement or license, an authorized-generic arrangement, or a legally sufficient carved label. A standard full-label launch before expiration would create substantial infringement risk.

Does the patent cover linagliptin with metformin?

The quoted claims do not expressly require metformin. They may be relevant to a linagliptin-metformin product when the product is administered for type 2 diabetes, but product-specific Orange Book listings and claim construction control.

Are biosimilars relevant to linagliptin?

No. Linagliptin is a chemically synthesized small molecule. Competitors would generally use the ANDA pathway for generic approval, not the biosimilar pathway under the Public Health Service Act.

Does patent expiration eliminate all U.S. exclusivity for Tradjenta?

No. Expiration of Patent 8,119,648 removes one barrier. Other listed patents, regulatory exclusivity, litigation settlements, formulation rights, combination-product patents, and manufacturing patents may affect market entry.

References

United States Patent and Trademark Office. (2012). U.S. Patent No. 8,119,648, Xanthine derivatives for the treatment of type 2 diabetes and obesity.
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, Orange Book.
United States Patent and Trademark Office. (2008). U.S. Patent No. 7,407,955, Xanthine derivatives.
U.S. Food and Drug Administration. (2011). FDA approves Tradjenta to treat type 2 diabetes.
Hatch, Waxman, and generic drug approval provisions, 21 U.S.C. § 355(j); 35 U.S.C. § 271(e)(2).

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
Germany	102 38 243	Aug 21, 2002
Germany	103 12 353	Mar 20, 2003

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	1532149	⤷ Start Trial	C300504	Netherlands	⤷ Start Trial
European Patent Office	1532149	⤷ Start Trial	1190035-4	Sweden	⤷ Start Trial
European Patent Office	1532149	⤷ Start Trial	PA2011013	Lithuania	⤷ Start Trial
European Patent Office	1532149	⤷ Start Trial	C20110018 00046	Estonia	⤷ Start Trial
European Patent Office	1532149	⤷ Start Trial	91889	Luxembourg	⤷ Start Trial
European Patent Office	1532149	⤷ Start Trial	CA 2011 00030	Denmark	⤷ Start Trial
European Patent Office	1532149	⤷ Start Trial	PA2011013,C1532149	Lithuania	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Summary for Patent: 8,119,648